NCT02105870

A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function

A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University of Melbourne · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients suffering an acute myocardial infarction. The investigators hypothesise that treatment with intracoronary abciximab, a potent anti platelet agent, at the time of coronary stent insertion, will improve microvascular function.

Detailed description

The index of microcirculatory resistance (IMR), an invasive measure of coronary microvascular function, correlates with clinical outcomes in patients with stable angina and ST elevation myocardial infarction. The glycoprotein IIb/IIIa receptor inhibitor, abciximab, improves coronary microvascular function and reduces major cardiac adverse events in patients with acute coronary syndromes. This study will investigate whether an intracoronary bolus of abciximab in patients with non-ST elevation myocardial infarction decreases IMR and improves microvascular function.

Conditions

• Myocardial Infarction
• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Abciximab	This drug will be administered intracoronary before percutaneous coronary intervention.

Timeline

• Start date: 2012-02-01
• Primary completion: 2014-06-01
• Completion: 2014-06-01
• First posted: 2014-04-07
• Last updated: 2014-04-07

Locations

1 site across 1 country: Australia